Horizon Therapeutics: Combining generic pain meds for greater drug safety
Palo Alto, Calif.-based Horizon Therapeutics, a biotech that aims to combine existing generic drugs to fight pain, raised $30 million in a third funding round. The company’s lead drug candidate, known only as HZT-501, is a “proprietary” combination of the generic drugs ibuprofen and famotidine, the latter of which is better known by its brand name Pepcid. It’s aimed at providing pain relief without gastrointestinal discomfort or injury, which is the same claim made by… Continue Reading
Horizon Therapeutics, stomach ulcer treatment co., raises $15M
Horizon Therapeutics, a Palo Alto company close to bringing its stomach ulcer drug into the third and last set of clinical trials, said it has raised $15 million in a second round of funding.
Its lead product is HZT-501, a “GI-friendly” prescription NSAID.
Scale Venture Partners, formerly known as BA Venture Partners, led the round. Sutter Hill Ventures and Pequot Ventures also participated. The Company completed a $6 million first round in October 2005 with the same… Continue Reading